Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H12O4 |
Molecular Weight | 268.2641 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CC1=CC2=C(OCC3=C(C=CC=C3)C2=O)C=C1
InChI
InChIKey=QFGMXJOBTNZHEL-UHFFFAOYSA-N
InChI=1S/C16H12O4/c17-15(18)8-10-5-6-14-13(7-10)16(19)12-4-2-1-3-11(12)9-20-14/h1-7H,8-9H2,(H,17,18)
Isoxepac (also known) as HP-549 is a non-steroidal anti-inflammatory drug with analgesic activity. Isoxepac was studied in the clinical trial for the treatment of postoperative pain after knee surgery for meniscectomy. It was shown, that 200 mg of isoxepac would appear to be the minimal effective dose. In case of rheumatoid arthritis, isoxepac showed significantly fewer adverse effects.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Quantitative analysis of 6,11-dihydro-11-oxo-dibenz[b,e] oxepin-2-acetic acid (isoxepac) in plasma and urine by gas--liquid chromatography. | 1978 May 1 |
|
Isoxepac in rheumatoid arthritis: a double-blind comparison with aspirin. | 1981 Feb 1 |
|
Local buccal mucosal effects of aspirin, indomethacin and isoxepac: their relationship to gastrointestinal damage. | 1981 May |
|
Analgesic effect of isoxepac on postmeniscectomy pain: a controlled trial. | 1982 Feb-Mar |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7013009
rheumatoid arthritis: 200 mg three times daily
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1478436
Created by
admin on Fri Dec 15 17:20:10 GMT 2023 , Edited by admin on Fri Dec 15 17:20:10 GMT 2023
|
PRIMARY | |||
|
m6554
Created by
admin on Fri Dec 15 17:20:10 GMT 2023 , Edited by admin on Fri Dec 15 17:20:10 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID8057772
Created by
admin on Fri Dec 15 17:20:10 GMT 2023 , Edited by admin on Fri Dec 15 17:20:10 GMT 2023
|
PRIMARY | |||
|
2KH283Q0Z5
Created by
admin on Fri Dec 15 17:20:10 GMT 2023 , Edited by admin on Fri Dec 15 17:20:10 GMT 2023
|
PRIMARY | |||
|
C166578
Created by
admin on Fri Dec 15 17:20:10 GMT 2023 , Edited by admin on Fri Dec 15 17:20:10 GMT 2023
|
PRIMARY | |||
|
C014904
Created by
admin on Fri Dec 15 17:20:10 GMT 2023 , Edited by admin on Fri Dec 15 17:20:10 GMT 2023
|
PRIMARY | |||
|
3310
Created by
admin on Fri Dec 15 17:20:10 GMT 2023 , Edited by admin on Fri Dec 15 17:20:10 GMT 2023
|
PRIMARY | |||
|
SUB08343MIG
Created by
admin on Fri Dec 15 17:20:10 GMT 2023 , Edited by admin on Fri Dec 15 17:20:10 GMT 2023
|
PRIMARY | |||
|
300907
Created by
admin on Fri Dec 15 17:20:10 GMT 2023 , Edited by admin on Fri Dec 15 17:20:10 GMT 2023
|
PRIMARY | |||
|
4246
Created by
admin on Fri Dec 15 17:20:10 GMT 2023 , Edited by admin on Fri Dec 15 17:20:10 GMT 2023
|
PRIMARY | |||
|
41448
Created by
admin on Fri Dec 15 17:20:10 GMT 2023 , Edited by admin on Fri Dec 15 17:20:10 GMT 2023
|
PRIMARY | |||
|
100000082838
Created by
admin on Fri Dec 15 17:20:10 GMT 2023 , Edited by admin on Fri Dec 15 17:20:10 GMT 2023
|
PRIMARY | |||
|
55453-87-7
Created by
admin on Fri Dec 15 17:20:10 GMT 2023 , Edited by admin on Fri Dec 15 17:20:10 GMT 2023
|
PRIMARY | |||
|
CHEMBL33211
Created by
admin on Fri Dec 15 17:20:10 GMT 2023 , Edited by admin on Fri Dec 15 17:20:10 GMT 2023
|
PRIMARY |
ACTIVE MOIETY